Today news
About the same in other media
Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab
Reading now: 255
Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
As part of the agreement BioFactura will receive license fees of a total not exceeding $33.5 million spread across different milestones leading to commercialization in regulated markets. A profit-sharing arrangement has been agreed by both the parties with CuraTeQ receiving 57 — 60% of the profits depending upon the markets.
Read more on economictimes.indiatimes.comAbout this in other media
Nevada Woman Sentenced to 5 Years for Trying to Hire Hitman with Bitcoin cryptonews.com /1 year ago
US weather update: Severe thunderstorm issued for several areas in Kansas City; Details here economictimes.indiatimes.com /1 year ago
Coinbase vs SEC court dates confirmed for initial case arguments cointelegraph.com /1 year ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
